IONQ, RGTI, QBTS: Quantum Hype Meets $931 Million in Insider Selling

Quantum computing stocks are rallying again. IONQ, RGTI, and QBTS all surged today - up roughly 7% to 9% on heavy volume - as the market chases the latest government-catalyzed wave of enthusiasm. The June executive orders on quantum hardware and cryptographic defense, combined with a $2 billion CHIPS Act allocation, have turned the sector into a retail magnet. But the numbers behind the headlines tell a story the narrative doesn't want you to read.

The three pure-play quantum stocks collectively carry a price-to-sales multiple that no profitability-focused investor can defend. IonQ trades at 83 times trailing sales. As of late May 2026, D-Wave sits at roughly 790 times. Rigetti, at 836 times, is so far beyond any conventional framework that the multiple is less a valuation metric than a measure of pure speculative premium. These aren't "early-stage startup" multiples. Even companies selling vaporware don't command this kind of premium without a path to revenue that investors can at least project.

Let's look at what the revenue actually says.

IonQ is the closest thing to a leader in this group. Its first-quarter 2026 revenue hit $64.7 million, a 755% year-over-year jump that management rightly highlighted. The company raised full-year guidance to $260 million–$270 million. That growth is real, and the remaining performance obligations - $470 million, up 554% year-over-year - suggest demand is building. But growth rate alone doesn't justify a $15.6 billion market cap when the company burned through $424 million in free cash flow over the trailing twelve months. IonQ's operating margin is minus 443%. Its return on invested capital is minus 27%. The company holds $3.1 billion in cash, cash equivalents, and investments, which keeps it solvent, but it's spending that runway at a pace that means future dilution or debt is not a maybe - it's a mathematical certainty if revenue doesn't compound at an exponential rate for several more years.

Rigetti reported $4.4 million in first-quarter revenue with a $26 million operating loss. That's a company generating roughly $17 million in annualized revenue that trades at a $5 billion-plus market cap. The recently signed CHIPS Act letter of intent for up to $100 million over three years is real federal support, but it's also a reminder that Rigetti needs government backing to survive - not that it has achieved commercial independence.

D-Wave is the most revealing case. Revenue fell 81% year-over-year to $2.9 million in the first quarter. The company's gross margin compressed from 92.5% to 63.6%. Operating expenses jumped 125%. The net loss widened to $18.4 million from $5.4 million. D-Wave's counterargument is bookings - $33.4 million in Q1, up nearly 2,000% from a year ago. Bookings are meaningful when they convert to recognized revenue, but quantum system sales take months or quarters to install, commission, and recognize. The 81% revenue decline tells you what actually hit the income statement this quarter.

Here's the question the bull narrative doesn't want you to ask: why have insiders at these three companies sold $931 million more stock than they've bought over the past five years? IonQ insiders alone have been net sellers of $576 million. D-Wave insiders have sold $295 million net. Rigetti insiders, $60 million. The buying side totals roughly $4.3 million across all three. Insiders sell for many reasons - tax obligations, diversification, personal liquidity - and not all selling is bearish. But the reverse is also true: insiders buy for only one reason, and they aren't buying their own companies.

I must admit I've been puzzled by the retail enthusiasm here. The June 22 executive orders and the $2 billion CHIPS allocation are legitimate policy tailwinds. The federal government is creating structured procurement timelines with hard deadlines - a 2028 target for a science-enabling quantum computer, a 2030-to-2031 post-quantum cryptography migration. That's a real pipeline. But policy support and commercial profitability are not the same thing, and government contracts don't automatically translate into investor returns when the stock has already priced in a near-perfect execution scenario over the next decade.

The price action reflects this disconnect. IonQ is trading at $41.72, down roughly 50% from its 52-week high of $84.64. The stock recently dropped 27% over a 30-day stretch, only recovering modestly on today's policy-driven rally. D-Wave sits at $21.83, down about 53% from its 52-week high of $46.75. The technical picture is neutral at best - IonQ's RSI is at 52, D-Wave's at 57 - neither flashing exhaustion nor confirming momentum. These are stocks that have fallen sharply and are now bouncing on headline catalysts, which is exactly the setup that lures retail buyers into catching what still looks like a descending trend.

The quantum computing thesis isn't wrong. The technology is real, the addressable market is enormous - Boston Consulting Group estimates $850 billion in global economic value by 2040 - and government policy is now actively funding the build-out. But the market's current pricing for these three stocks assumes flawless execution, zero competitive disruption from big-tech players like IBM, Google, and Amazon, and a timeline to profitability that hasn't materialized despite years of investment. When insiders are selling nine hundred and thirty-one million dollars worth of stock while retail traders chase government headlines, the risk/reward has arguably tilted toward the sellers.

Don't chase this rally. The quantum opportunity is real, but the current valuations have baked in a decade of perfect execution. The better risk/reward for investors interested in this space is to wait for either a meaningful pullback that brings these multiples closer to something defensible, or for at least one of these companies to demonstrate a credible path to positive free cash flow. Until then, the gap between the vision and the numbers remains too wide.

I would reassess this posture if IonQ can show free cash flow narrowing toward breakeven on a trailing basis, if D-Wave's bookings convert to recognized revenue at a rate that justifies its current multiple, or if Rigetti demonstrates that its CHIPS Act funding is catalyzing genuine commercial scale rather than just balance-sheet relief. Absent those signals, these stocks remain a narrative play, not a fundamental investment.